[HTML][HTML] Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda, L Beppu… - PLoS …, 2022 - journals.plos.org
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR:: ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda, L Beppu… - PLOS ONE, 2022 - ideas.repec.org
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR:: ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda… - PLOS …, 2022 - econpapers.repec.org
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR:: ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda, L Beppu… - PLoS ONE, 2022 - go.gale.com
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15-20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15-20% of all cases of leukemia. CML is caused by a translocation between …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR:: ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda… - PloS …, 2022 - pubmed.ncbi.nlm.nih.gov
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15-20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15-20% of all cases of leukemia. CML is caused by a translocation between …
[HTML][HTML] Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR:: ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda, L Beppu… - PLoS ONE, 2022 - ncbi.nlm.nih.gov
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR:: ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda… - PLoS …, 2022 - search.ebscohost.com
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR:: ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda… - PLoS …, 2022 - ui.adsabs.harvard.edu
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR:: ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda, L Beppu… - Plos one, 2022 - europepmc.org
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR:: ABL1 monitoring in chronic …
DN Shelton, P Bhagavatula, N Sepulveda, L Beppu… - Plos one, 2022 - europepmc.org
Chronic myelogenous leukemia (CML) is a hematopoietic stem cell malignancy that
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …
accounts for 15–20% of all cases of leukemia. CML is caused by a translocation between …